Seasoned investment professionals, sector-dedicated analysts, and creative thinkers are at the heart of our business. Get their perspective on today's market climate.

Video Transcript

Introduction to Generics and Biosimilars

TOM BUTCHER: What are generic drugs, and why are they important?

JAMES DUFFY: Generic drugs are drugs that are comparable to their brand-name counterparts. They are comparable in terms of the dosage, effectiveness, and intended use. Generics are important because they are essentially a less-expensive alternative to their brand-name counterparts. This, of course, is going to be important to those who are ultimately picking up the tab, governments, who are the biggest purchasers of health care, insurance companies, and individuals.

BUTCHER: Is there a generic drug for each branded drug?

DUFFY: No, there is not. One of the biggest reasons for this is that when new drugs are approved and brought onto the market, they are usually afforded a certain period of patent protection and exclusivity. Now, these patent protections and exclusivity periods will vary from country to country. Once these periods expire, prevailing market conditions will usually kick in and determine whether or not a generic variant is manufactured.

BUTCHER: Going back to what you said about generics being a cheaper alternative, why are they cheaper?

DUFFY: The barriers to generic markets are usually a lot lower. If we look at the United States, back in 1984 they passed the Hatch-Waxman Act and essentially what this did was allow for an expedited approval process for generics. Prior to that, any generic coming onto the market had to prove the effectiveness of the drug. That has been changed since the effectiveness of the brand-name drug was already proven. All generics are required to do now is to prove that they are a comparable drug to the brand-name drug.

BUTCHER: You mentioned the United States. Is generic drug manufacturing and use global?

DUFFY: It is global. As of 2015, about 88% of all U.S. prescriptions are filled with generics. Looking over at Europe, that number is about 55%. And if we look at Japan over in the Asia-Pacific region, that number is about 47%.

BUTCHER: Are they manufactured in the U.S. and elsewhere?

DUFFY: It is a global business. They are manufacturing in the U.S., India happens to be a very large manufacturing area, as well as other countries. It truly is a global business.

BUTCHER: Many of the blockbuster pharmaceutical drugs are now off patent. What does the future hold for generic drug manufacturers?

DUFFY: We believe that the future of generics lies within biosimilars. Biosimilars are essentially the generic form of biotech drugs. Biotechs are the drugs that we have heard so much about over the past ten or fifteen years. What is exciting about this space is that the anticipated margins are supposed to be higher than that of their chemically-synthesized counterparts. Biosimilars are expected to be sold at anywhere from a 20 to 30% discount to the brand name, where chemically synthesized generics are sold at an approximately 50 to 80% discount1.

BUTCHER: Wonderful. Jim, thank you very much indeed.

DUFFY: Thank you.

- - - - - - - - - -

1Source: Indxx.

This content is published in the United States for residents of specified countries. Investors are subject to securities and tax regulations within their applicable jurisdictions that are not addressed on this content. Nothing in this content should be considered a solicitation to buy or an offer to sell shares of any investment in any jurisdiction where the offer or solicitation would be unlawful under the securities laws of such jurisdiction, nor is it intended as investment, tax, financial, or legal advice. Investors should seek such professional advice for their particular situation and jurisdiction. You can obtain specific information on Van Eck Global strategies by visiting Investment Strategies.

The views and opinions expressed are those of the speaker and are current as of the video’s posting date. Video commentaries are general in nature and should not be construed as investment advice. Opinions are subject to change with market conditions. All performance information is historical and is not a guarantee of future results. For more information about Van Eck Funds, Market Vectors ETFs or fund performance, visit Any discussion of specific securities mentioned in the video commentaries is neither an offer to sell nor a solicitation to buy these securities. Fund holdings will vary. All indices mentioned are measures of common market sectors and performance. It is not possible to invest directly in an index. Information on holdings, performance and indices can be found at

Please note that Van Eck Securities Corporation offers investment products that invest in the asset class(es) included in this video. An investment in the Fund may be subject to risks which include, among others, the development, protection and exploitation of intellectual property rights, expiration of patents and inability to enforce intellectual property rights, significant costs associated with research and development and speculation that those investments will result in profitable products, arduous regulatory approval processes, rapid and significant technological change, uncertainty of reimbursement status by third-party payers such as Medicare, Medicaid and private health insurance plans. Foreign and emerging markets investments are subject to risks, which include changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations, changes in currency exchange rates, unstable governments, and limited trading capacity which may make these investments volatile in price or difficult to trade. Medium-capitalization companies may be subject to elevated risks. The Fund’s assets may be concentrated in a particular sector and may be subject to more risk than investments in a diverse group of sectors.

Investing involves risk, including possible loss of principal. An investor should carefully consider investment objectives, risks, charges and expenses of the investment company before investing. Bond and bond funds will decrease in value as interest rates rise. Call 800.826.2333 or click below to obtain a prospectus and summary prospectus which contain this and other information. Please read the prospectus and summary prospectus carefully before investing.

No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission of Van Eck Securities Corporation. © Van Eck Securities Corporation.

Van Eck Securities Corporation, Distributor
666 Third Avenue, New York, NY 10017